TCM
MLYS icon

TCG Crossover Management’s Mineralys Therapeutics MLYS Stock Holding History

TCG Crossover Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,470,265
Closed -$39.2M – 39
2025
Q1 		$39.2M Hold
2,470,265
– – 5.35% 4
2024
Q4 		$30.4M Hold
2,470,265
– – 2.97% 13
2024
Q3 		$29.9M Sell
2,470,265
-714,920
-22% -$8.65M 2.53% 17
2024
Q2 		$37.3M Hold
3,185,185
– – 3.88% 10
2024
Q1 		$41.1M Buy
+3,185,185
New +$39.3M 3.25% 14

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCG Crossover Management's MLYS Position: Q2 2025 in Review

TCG Crossover Management sold out of Mineralys Therapeutics (MLYS) in Q2 2025, closing a stake of 2,470,265 shares — an estimated $39.2M sold.

TCG Crossover Management first reported a position in MLYS in Q1 2024 and held it in 5 quarters. The position peaked at $41.1M in Q1 2024. 165 funds tracked by Wall St. Rank hold MLYS as of Q2 2025.

  • TCG Crossover Management reported no remaining Mineralys Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TCG Crossover Management sold 2,470,265 Mineralys Therapeutics shares in Q2 2025, an estimated $39.2M.
  • TCG Crossover Management first reported a position in Mineralys Therapeutics in Q1 2024 and held it in 5 quarters.
  • TCG Crossover Management's Mineralys Therapeutics position peaked at $41.1M in Q1 2024.
  • 165 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2025.

Based on TCG Crossover Management's 13F filing for Q2 2025, filed 14 Aug 2025.